1.33
price up icon9.02%   0.11
pre-market  プレマーケット:  1.37   0.04   +3.01%
loading
前日終値:
$1.22
開ける:
$1.3301
24時間の取引高:
2.05M
Relative Volume:
0.47
時価総額:
$263.61M
収益:
$116.33M
当期純損益:
$-209.25M
株価収益率:
-0.6274
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
+18.75%
1か月 パフォーマンス:
+27.88%
6か月 パフォーマンス:
-36.06%
1年 パフォーマンス:
-43.16%
1日の値動き範囲:
Value
$1.30
$1.37
1週間の範囲:
Value
$1.105
$1.37
52週間の値動き範囲:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
名前
Esperion Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
734-887-3903
Name
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
職員
304
Name
Twitter
@esperioninc
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
ESPR's Discussions on Twitter

ESPR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
1.33 241.80M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.45 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.74 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.58 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.61 13.44B 2.99B 1.21B 1.13B 25.06

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-18 開始されました Goldman Neutral
2024-12-17 開始されました Cantor Fitzgerald Overweight
2024-06-20 ダウングレード BofA Securities Neutral → Underperform
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-11-20 再開されました JP Morgan Neutral
2023-08-01 アップグレード Northland Capital Under Perform → Market Perform
2023-06-15 アップグレード BofA Securities Underperform → Buy
2023-03-16 ダウングレード BofA Securities Neutral → Underperform
2023-03-16 ダウングレード Northland Capital Market Perform → Under Perform
2023-03-07 アップグレード Credit Suisse Underperform → Neutral
2023-02-27 再開されました BofA Securities Neutral
2023-02-24 アップグレード Jefferies Hold → Buy
2023-02-03 アップグレード Morgan Stanley Underweight → Equal-Weight
2022-08-03 ダウングレード Credit Suisse Neutral → Underperform
2022-05-05 アップグレード JP Morgan Underweight → Neutral
2022-03-10 開始されました H.C. Wainwright Buy
2021-10-19 ダウングレード Credit Suisse Outperform → Neutral
2021-10-14 ダウングレード Morgan Stanley Equal-Weight → Underweight
2021-05-05 ダウングレード Stifel Buy → Hold
2021-04-26 再開されました Credit Suisse Outperform
2021-03-11 開始されました Morgan Stanley Equal-Weight
2021-02-12 ダウングレード Jefferies Buy → Hold
2021-02-09 ダウングレード Goldman Neutral → Sell
2021-01-15 ダウングレード BofA Securities Buy → Neutral
2020-11-10 アップグレード Credit Suisse Neutral → Outperform
2020-09-29 再開されました JP Morgan Underweight
2020-08-11 ダウングレード Credit Suisse Outperform → Neutral
2020-04-01 再開されました BofA/Merrill Buy
2020-03-17 アップグレード Citigroup Neutral → Buy
2020-02-24 ダウングレード Northland Capital Outperform → Market Perform
2020-02-14 ダウングレード Citigroup Buy → Neutral
2019-09-16 アップグレード Goldman Sell → Neutral
2019-05-29 ダウングレード Goldman Neutral → Sell
2019-05-06 アップグレード BofA/Merrill Underperform → Neutral
2019-04-26 アップグレード Goldman Sell → Neutral
2019-03-13 アップグレード JP Morgan Underweight → Neutral
2019-01-07 繰り返されました Needham Strong Buy
2018-12-13 開始されました Goldman Sell
2018-10-29 アップグレード Northland Capital Market Perform → Outperform
2018-10-16 開始されました BTIG Research Buy
2018-08-17 アップグレード Citigroup Neutral → Buy
2018-07-11 ダウングレード Northland Capital Outperform → Market Perform
2018-05-03 ダウングレード JP Morgan Neutral → Underweight
2018-05-02 ダウングレード BofA/Merrill Buy → Underperform
すべてを表示

Esperion Therapeutics Inc (ESPR) 最新ニュース

pulisher
Jul 23, 2025

Esperion Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Esperion Therapeutics Inc. stockExplosive earning power - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Esperion Therapeutics Inc. a good long term investmentAccelerated profit realization - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5 - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 15, 2025

How Esperion Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 09, 2025

Esperion settles litigation with Accord Healthcare - MSN

Jul 09, 2025
pulisher
Jul 08, 2025

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040 - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Secures Extended NEXLETOL Patent Protection: A Strategic Play for Market Dominance - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR) - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 01, 2025

Esperion Appoints Craig Thompson to Board of Directors - GlobeNewswire

Jul 01, 2025
pulisher
Jul 01, 2025

Esperion Expands Board with New Appointment - TipRanks

Jul 01, 2025
pulisher
Jun 27, 2025

Dyslipidemia Market is expected to reach US$ 40.33 Billion - openPR.com

Jun 27, 2025
pulisher
Jun 17, 2025

ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Racing Teams Up with Esperion for the Wellness Walk at Pocono - Speedway Digest

Jun 17, 2025
pulisher
Jun 16, 2025

Esperion Therapeutics Soars 19.66% on Positive Clinical Data, Debt Restructuring - AInvest

Jun 16, 2025
pulisher
Jun 14, 2025

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha

Jun 14, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 04, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia

Jun 04, 2025
pulisher
Jun 03, 2025

ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

MarketsMedicine Hat News - FinancialContent

Jun 02, 2025
pulisher
May 31, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World

May 31, 2025
pulisher
May 31, 2025

Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World

May 31, 2025
pulisher
May 31, 2025

Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World

May 30, 2025

Esperion Therapeutics Inc (ESPR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$73.31
price up icon 1.34%
$15.02
price up icon 0.60%
$9.37
price up icon 1.41%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$133.66
price up icon 0.69%
$305.61
price up icon 2.59%
大文字化:     |  ボリューム (24 時間):